Summary for symposium I on the development of a more efficacious influenza vaccine held at the 15th Annual Meeting of the Japanese Society for Vaccinology, Tokyo, 2011.
Influenza HA split vaccine is widely administered to children and adults worldwide. However, its limited efficacy and weak potential to control the next influenza pandemic has recently been emphasized and has raised serious concerns. These circumstances led the Japanese Society for Vaccinology to organize this symposium to discuss the next generation of influenza vaccine which should be more efficacious and much safer. The symposium covered data assessment of the newly developed H5N1 vaccine, adjuvant development for influenza vaccine, the future threat of H5N1 influenza, measures for its control, and the recent development of a mucosal vaccine.
Kohjinkai Health Care, Kumagai Pediatric Clinic, West 6, Momijidai, Atsubetsu-Ku, Sapporo 004-0013, Japan. tkuma@mb.infosnow.ne.jp
Takuji
T
Kumagai
Hiroshi
H
Kiyono
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D058956:Administration, Mucosal; D055808:Drug Discovery / Q000639:trends*; D006801:Humans; D053124:Influenza A Virus, H5N1 Subtype / Q000235:genetics / Q000276:immunology; D007252:Influenza Vaccines / Q000235:genetics / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control*; D014041:Tokyo
D000276:Adjuvants, Immunologic; D007252:Influenza Vaccines